CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial
Identifieur interne : 000C77 ( Ncbi/Merge ); précédent : 000C76; suivant : 000C78CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial
Auteurs : J. Alexandre [France] ; C. Brown [Australie] ; D. Coeffic [France] ; N. Raban [France] ; J. Pfisterer [Allemagne] ; J. M Enp [Finlande] ; H. Chalchal ; B. Fitzharris [Nouvelle-Zélande] ; B. Volgger [Autriche] ; I. Vergote [Belgique] ; C. Pisano [Italie] ; A. Ferrero [Italie] ; E. Pujade-Lauraine [France]Source :
- British Journal of Cancer [ 0007-0920 ] ; 2012.
Abstract
CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remains controversial. CALYPSO is a large randomised trial incorporating CA-125 (GCIG criteria) and symptomatic deterioration in addition to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (radiological) to determine progression.
In all, 976 patients with platinum-sensitive ROC were randomised to carboplatin–paclitaxel (C-P) or carboplatin-pegylated liposomal doxorubicin (C-PLD). CT-scan and CA-125 were performed every 3 months until progression.
In all, 832 patients (85%) progressed, with 60% experiencing a first radiological progression, 10% symptomatic progression, and 28% CA-125 progression without evidence of radiological or symptomatic progression. The benefit of C-PLD
CA-125 and radiological tests performed similarly in determining progression with C-PLD or C-P. Additional follow-up with CA-125 measurements was not associated with overtreatment.
Url:
DOI: 10.1038/bjc.2011.593
PubMed: 22240800
PubMed Central: 3322951
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000077
- to stream Pmc, to step Curation: 000077
- to stream Pmc, to step Checkpoint: 002031
Links to Exploration step
PMC:3322951Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial</title><author><name sortKey="Alexandre, J" sort="Alexandre, J" uniqKey="Alexandre J" first="J" last="Alexandre">J. Alexandre</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Département d'Oncologie Médicale, Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre</institution>, site Hôtel-Dieu, Paris,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Brown, C" sort="Brown, C" uniqKey="Brown C" first="C" last="Brown">C. Brown</name><affiliation wicri:level="1"><nlm:aff id="aff2"><institution>NHMRC Clinical Trials Centre</institution>, Sydney,<country>Australia</country></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Coeffic, D" sort="Coeffic, D" uniqKey="Coeffic D" first="D" last="Coeffic">D. Coeffic</name><affiliation wicri:level="1"><nlm:aff id="aff3"><institution>Medical Oncology Department, Hôpital des Diaconesses</institution>, Paris,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Raban, N" sort="Raban, N" uniqKey="Raban N" first="N" last="Raban">N. Raban</name><affiliation wicri:level="1"><nlm:aff id="aff4"><institution>Department of Medical Oncology, University Hospital of Milétrie</institution>, Poitiers,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Pfisterer, J" sort="Pfisterer, J" uniqKey="Pfisterer J" first="J" last="Pfisterer">J. Pfisterer</name><affiliation wicri:level="1"><nlm:aff id="aff5"><institution>Department of Gynecology, Staedtisches Klinikum Solingen</institution>, Solingen,<country>Germany</country></nlm:aff><country xml:lang="fr">Allemagne</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="M Enp, J" sort="M Enp, J" uniqKey="M Enp J" first="J" last="M Enp">J. M Enp</name><affiliation wicri:level="1"><nlm:aff id="aff6"><institution>Department of Obstetrics and Gynecology, University of Tampere and Tampere University Hospital</institution>, Tampere,<country>Finland</country></nlm:aff><country xml:lang="fr">Finlande</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Chalchal, H" sort="Chalchal, H" uniqKey="Chalchal H" first="H" last="Chalchal">H. Chalchal</name><affiliation><nlm:aff id="aff7"><institution>Department of Medicine, University of Saskatchewan. Allan Blair Cancer Centre</institution>, Regina,<country>Saskatchewan</country></nlm:aff><wicri:noCountry code="nlm country">Saskatchewan</wicri:noCountry></affiliation></author><author><name sortKey="Fitzharris, B" sort="Fitzharris, B" uniqKey="Fitzharris B" first="B" last="Fitzharris">B. Fitzharris</name><affiliation wicri:level="1"><nlm:aff id="aff8"><institution>Christchurch Hospital</institution>, Christchurch,<country>New Zealand</country></nlm:aff><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Volgger, B" sort="Volgger, B" uniqKey="Volgger B" first="B" last="Volgger">B. Volgger</name><affiliation wicri:level="1"><nlm:aff id="aff9"><institution>Department of Obstetrics and Gynecology, University Hospital Innsbruck</institution>, Innsbruck,<country>Austria</country></nlm:aff><country xml:lang="fr">Autriche</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Vergote, I" sort="Vergote, I" uniqKey="Vergote I" first="I" last="Vergote">I. Vergote</name><affiliation wicri:level="1"><nlm:aff id="aff10"><institution>University Hospital Leuven, Leuven Cancer Institute and Department of Gynaecological Oncology</institution>, Leuven,<country>Belgium</country></nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Pisano, C" sort="Pisano, C" uniqKey="Pisano C" first="C" last="Pisano">C. Pisano</name><affiliation wicri:level="1"><nlm:aff id="aff11"><institution>Division of Medical Oncology, Uro-Gynecological Department, National Cancer Institute</institution>, Naples,<country>Italy</country></nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Ferrero, A" sort="Ferrero, A" uniqKey="Ferrero A" first="A" last="Ferrero">A. Ferrero</name><affiliation wicri:level="1"><nlm:aff id="aff12"><institution>Academic Division of Gynecologic Oncology, Mauriziano Hospital</institution>, Torino,<country>Italy</country></nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E" last="Pujade-Lauraine">E. Pujade-Lauraine</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Département d'Oncologie Médicale, Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre</institution>, site Hôtel-Dieu, Paris,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22240800</idno><idno type="pmc">3322951</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322951</idno><idno type="RBID">PMC:3322951</idno><idno type="doi">10.1038/bjc.2011.593</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">000077</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000077</idno><idno type="wicri:Area/Pmc/Curation">000077</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000077</idno><idno type="wicri:Area/Pmc/Checkpoint">002031</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002031</idno><idno type="wicri:Area/Ncbi/Merge">000C77</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial</title><author><name sortKey="Alexandre, J" sort="Alexandre, J" uniqKey="Alexandre J" first="J" last="Alexandre">J. Alexandre</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Département d'Oncologie Médicale, Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre</institution>, site Hôtel-Dieu, Paris,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Brown, C" sort="Brown, C" uniqKey="Brown C" first="C" last="Brown">C. Brown</name><affiliation wicri:level="1"><nlm:aff id="aff2"><institution>NHMRC Clinical Trials Centre</institution>, Sydney,<country>Australia</country></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Coeffic, D" sort="Coeffic, D" uniqKey="Coeffic D" first="D" last="Coeffic">D. Coeffic</name><affiliation wicri:level="1"><nlm:aff id="aff3"><institution>Medical Oncology Department, Hôpital des Diaconesses</institution>, Paris,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Raban, N" sort="Raban, N" uniqKey="Raban N" first="N" last="Raban">N. Raban</name><affiliation wicri:level="1"><nlm:aff id="aff4"><institution>Department of Medical Oncology, University Hospital of Milétrie</institution>, Poitiers,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Pfisterer, J" sort="Pfisterer, J" uniqKey="Pfisterer J" first="J" last="Pfisterer">J. Pfisterer</name><affiliation wicri:level="1"><nlm:aff id="aff5"><institution>Department of Gynecology, Staedtisches Klinikum Solingen</institution>, Solingen,<country>Germany</country></nlm:aff><country xml:lang="fr">Allemagne</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="M Enp, J" sort="M Enp, J" uniqKey="M Enp J" first="J" last="M Enp">J. M Enp</name><affiliation wicri:level="1"><nlm:aff id="aff6"><institution>Department of Obstetrics and Gynecology, University of Tampere and Tampere University Hospital</institution>, Tampere,<country>Finland</country></nlm:aff><country xml:lang="fr">Finlande</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Chalchal, H" sort="Chalchal, H" uniqKey="Chalchal H" first="H" last="Chalchal">H. Chalchal</name><affiliation><nlm:aff id="aff7"><institution>Department of Medicine, University of Saskatchewan. Allan Blair Cancer Centre</institution>, Regina,<country>Saskatchewan</country></nlm:aff><wicri:noCountry code="nlm country">Saskatchewan</wicri:noCountry></affiliation></author><author><name sortKey="Fitzharris, B" sort="Fitzharris, B" uniqKey="Fitzharris B" first="B" last="Fitzharris">B. Fitzharris</name><affiliation wicri:level="1"><nlm:aff id="aff8"><institution>Christchurch Hospital</institution>, Christchurch,<country>New Zealand</country></nlm:aff><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Volgger, B" sort="Volgger, B" uniqKey="Volgger B" first="B" last="Volgger">B. Volgger</name><affiliation wicri:level="1"><nlm:aff id="aff9"><institution>Department of Obstetrics and Gynecology, University Hospital Innsbruck</institution>, Innsbruck,<country>Austria</country></nlm:aff><country xml:lang="fr">Autriche</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Vergote, I" sort="Vergote, I" uniqKey="Vergote I" first="I" last="Vergote">I. Vergote</name><affiliation wicri:level="1"><nlm:aff id="aff10"><institution>University Hospital Leuven, Leuven Cancer Institute and Department of Gynaecological Oncology</institution>, Leuven,<country>Belgium</country></nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Pisano, C" sort="Pisano, C" uniqKey="Pisano C" first="C" last="Pisano">C. Pisano</name><affiliation wicri:level="1"><nlm:aff id="aff11"><institution>Division of Medical Oncology, Uro-Gynecological Department, National Cancer Institute</institution>, Naples,<country>Italy</country></nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Ferrero, A" sort="Ferrero, A" uniqKey="Ferrero A" first="A" last="Ferrero">A. Ferrero</name><affiliation wicri:level="1"><nlm:aff id="aff12"><institution>Academic Division of Gynecologic Oncology, Mauriziano Hospital</institution>, Torino,<country>Italy</country></nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E" last="Pujade-Lauraine">E. Pujade-Lauraine</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Département d'Oncologie Médicale, Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre</institution>, site Hôtel-Dieu, Paris,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></analytic><series><title level="j">British Journal of Cancer</title><idno type="ISSN">0007-0920</idno><idno type="eISSN">1532-1827</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background:</title><p>CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remains controversial. CALYPSO is a large randomised trial incorporating CA-125 (GCIG criteria) and symptomatic deterioration in addition to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (radiological) to determine progression.</p></sec><sec><title>Methods:</title><p>In all, 976 patients with platinum-sensitive ROC were randomised to carboplatin–paclitaxel (C-P) or carboplatin-pegylated liposomal doxorubicin (C-PLD). CT-scan and CA-125 were performed every 3 months until progression.</p></sec><sec><title>Results:</title><p>In all, 832 patients (85%) progressed, with 60% experiencing a first radiological progression, 10% symptomatic progression, and 28% CA-125 progression without evidence of radiological or symptomatic progression. The benefit of C-PLD <italic>vs</italic> C-P in progression-free survival was not influenced by type of first progression (hazard ratio 0.85 (95% confidence interval (CI): 0.66–1.10) and 0.84 (95% CI: 0.72–0.98) for CA-125 and RECIST, respectively). In patients with CA-125 first progression who subsequently progressed radiologically, a delay of 2.3 months was observed between the two progression types. After CA-125 first progression, median time to new treatment was 2.0 months. In all, 81%of the patients with CA-125 or radiological first progression and 60% with symptomatic first progression received subsequent treatment.</p></sec><sec><title>Conclusion:</title><p>CA-125 and radiological tests performed similarly in determining progression with C-PLD or C-P. Additional follow-up with CA-125 measurements was not associated with overtreatment.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Bast, Rc" uniqKey="Bast R">RC Bast</name></author><author><name sortKey="Thigpen, Jt" uniqKey="Thigpen J">JT Thigpen</name></author><author><name sortKey="Arbuck, Sg" uniqKey="Arbuck S">SG Arbuck</name></author><author><name sortKey="Basen Engquist, K" uniqKey="Basen Engquist K">K Basen-Engquist</name></author><author><name sortKey="Burke, Lb" uniqKey="Burke L">LB Burke</name></author><author><name sortKey="Freedman, R" uniqKey="Freedman R">R Freedman</name></author><author><name sortKey="Horning, Sj" uniqKey="Horning S">SJ Horning</name></author><author><name sortKey="Ozols, R" uniqKey="Ozols R">R Ozols</name></author><author><name sortKey="Rustin, Gj" uniqKey="Rustin G">GJ Rustin</name></author><author><name sortKey="Spriggs, D" uniqKey="Spriggs D">D Spriggs</name></author><author><name sortKey="Wenzel, Lb" uniqKey="Wenzel L">LB Wenzel</name></author><author><name sortKey="Pazdur, R" uniqKey="Pazdur R">R Pazdur</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burger, Ra" uniqKey="Burger R">RA Burger</name></author><author><name sortKey="Brady, Mf" uniqKey="Brady M">MF Brady</name></author><author><name sortKey="Bookman, Ma" uniqKey="Bookman M">MA Bookman</name></author><author><name sortKey="Walker, Jl" uniqKey="Walker J">JL Walker</name></author><author><name sortKey="Homesley, Hd" uniqKey="Homesley H">HD Homesley</name></author><author><name sortKey="Fowler, J" uniqKey="Fowler J">J Fowler</name></author><author><name sortKey="Monk, Bj" uniqKey="Monk B">BJ Monk</name></author><author><name sortKey="Greer, Be" uniqKey="Greer B">BE Greer</name></author><author><name sortKey="Boente, M" uniqKey="Boente M">M Boente</name></author><author><name sortKey="Liang, Sx" uniqKey="Liang S">SX Liang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Eisenhauer, Ea" uniqKey="Eisenhauer E">EA Eisenhauer</name></author><author><name sortKey="Therasse, P" uniqKey="Therasse P">P Therasse</name></author><author><name sortKey="Bogaerts, J" uniqKey="Bogaerts J">J Bogaerts</name></author><author><name sortKey="Schwartz, Lh" uniqKey="Schwartz L">LH Schwartz</name></author><author><name sortKey="Sargent, D" uniqKey="Sargent D">D Sargent</name></author><author><name sortKey="Ford, R" uniqKey="Ford R">R Ford</name></author><author><name sortKey="Dancey, J" uniqKey="Dancey J">J Dancey</name></author><author><name sortKey="Arbuck, S" uniqKey="Arbuck S">S Arbuck</name></author><author><name sortKey="Gwyther, S" uniqKey="Gwyther S">S Gwyther</name></author><author><name sortKey="Mooney, M" uniqKey="Mooney M">M Mooney</name></author><author><name sortKey="Rubinstein, L" uniqKey="Rubinstein L">L Rubinstein</name></author><author><name sortKey="Shankar, L" uniqKey="Shankar L">L Shankar</name></author><author><name sortKey="Dodd, L" uniqKey="Dodd L">L Dodd</name></author><author><name sortKey="Kaplan, R" uniqKey="Kaplan R">R Kaplan</name></author><author><name sortKey="Lacombe, D" uniqKey="Lacombe D">D Lacombe</name></author><author><name sortKey="Verweij, J" uniqKey="Verweij J">J Verweij</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Goonewardene, Ti" uniqKey="Goonewardene T">TI Goonewardene</name></author><author><name sortKey="Hall, Mr" uniqKey="Hall M">MR Hall</name></author><author><name sortKey="Rustin, Gjs" uniqKey="Rustin G">GJS Rustin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hennessy, Bt" uniqKey="Hennessy B">BT Hennessy</name></author><author><name sortKey="Coleman, Rl" uniqKey="Coleman R">RL Coleman</name></author><author><name sortKey="Markman, M" uniqKey="Markman M">M Markman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Joly, F" uniqKey="Joly F">F Joly</name></author><author><name sortKey="Ray Coquard, I" uniqKey="Ray Coquard I">I Ray-Coquard</name></author><author><name sortKey="Fabbro, M" uniqKey="Fabbro M">M Fabbro</name></author><author><name sortKey="Donoghoe, M" uniqKey="Donoghoe M">M Donoghoe</name></author><author><name sortKey="Boman, K" uniqKey="Boman K">K Boman</name></author><author><name sortKey="Sugimoto, A" uniqKey="Sugimoto A">A Sugimoto</name></author><author><name sortKey="Donoghoe, M" uniqKey="Donoghoe M">M Donoghoe</name></author><author><name sortKey="Boman, K" uniqKey="Boman K">K Boman</name></author><author><name sortKey="Sugimoto, A" uniqKey="Sugimoto A">A Sugimoto</name></author><author><name sortKey="Vaughan, M" uniqKey="Vaughan M">M Vaughan</name></author><author><name sortKey="Reinthaller, A" uniqKey="Reinthaller A">A Reinthaller</name></author><author><name sortKey="Vergote, I" uniqKey="Vergote I">I Vergote</name></author><author><name sortKey="Ferrandina, G" uniqKey="Ferrandina G">G Ferrandina</name></author><author><name sortKey="Dell Anna, T" uniqKey="Dell Anna T">T Dell'Anna</name></author><author><name sortKey="Huober, J" uniqKey="Huober J">J Huober</name></author><author><name sortKey="Pujade Lauraine, E" uniqKey="Pujade Lauraine E">E Pujade-Lauraine</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kurtz, Je" uniqKey="Kurtz J">JE Kurtz</name></author><author><name sortKey="Kaminsky, Mc" uniqKey="Kaminsky M">MC Kaminsky</name></author><author><name sortKey="Floquet, A" uniqKey="Floquet A">A Floquet</name></author><author><name sortKey="Veillard, As" uniqKey="Veillard A">AS Veillard</name></author><author><name sortKey="Kimmig, R" uniqKey="Kimmig R">R Kimmig</name></author><author><name sortKey="Dorum, A" uniqKey="Dorum A">A Dorum</name></author><author><name sortKey="Elit, L" uniqKey="Elit L">L Elit</name></author><author><name sortKey="Buck, M" uniqKey="Buck M">M Buck</name></author><author><name sortKey="Petru, E" uniqKey="Petru E">E Petru</name></author><author><name sortKey="Reed, N" uniqKey="Reed N">N Reed</name></author><author><name sortKey="Scambia, G" uniqKey="Scambia G">G Scambia</name></author><author><name sortKey="Varsellona, N" uniqKey="Varsellona N">N Varsellona</name></author><author><name sortKey="Brown, C" uniqKey="Brown C">C Brown</name></author><author><name sortKey="Pujade Lauraine, E" uniqKey="Pujade Lauraine E">E Pujade-Lauraine</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, Ck" uniqKey="Lee C">CK Lee</name></author><author><name sortKey="Friedlander, M" uniqKey="Friedlander M">M Friedlander</name></author><author><name sortKey="Brown, C" uniqKey="Brown C">C Brown</name></author><author><name sortKey="Gebski, Vj" uniqKey="Gebski V">VJ Gebski</name></author><author><name sortKey="Georgoulopoulos, A" uniqKey="Georgoulopoulos A">A Georgoulopoulos</name></author><author><name sortKey="Vergote, I" uniqKey="Vergote I">I Vergote</name></author><author><name sortKey="Pignata, S" uniqKey="Pignata S">S Pignata</name></author><author><name sortKey="Donadello, N" uniqKey="Donadello N">N Donadello</name></author><author><name sortKey="Schmalfeldt, B" uniqKey="Schmalfeldt B">B Schmalfeldt</name></author><author><name sortKey="Delva, R" uniqKey="Delva R">R Delva</name></author><author><name sortKey="Mirza, Mr" uniqKey="Mirza M">MR Mirza</name></author><author><name sortKey="Sauthier, P" uniqKey="Sauthier P">P Sauthier</name></author><author><name sortKey="Pujade Lauraine, E" uniqKey="Pujade Lauraine E">E Pujade-Lauraine</name></author><author><name sortKey="Lord, Sj" uniqKey="Lord S">SJ Lord</name></author><author><name sortKey="Simes, Rj" uniqKey="Simes R">RJ Simes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pujade Lauraine, E" uniqKey="Pujade Lauraine E">E Pujade-Lauraine</name></author><author><name sortKey="Wagner, U" uniqKey="Wagner U">U Wagner</name></author><author><name sortKey="Aavall Lundqvist, E" uniqKey="Aavall Lundqvist E">E Aavall-Lundqvist</name></author><author><name sortKey="Gebski, V" uniqKey="Gebski V">V Gebski</name></author><author><name sortKey="Heywood, M" uniqKey="Heywood M">M Heywood</name></author><author><name sortKey="Vasey, Pa" uniqKey="Vasey P">PA Vasey</name></author><author><name sortKey="Volgger, B" uniqKey="Volgger B">B Volgger</name></author><author><name sortKey="Vergote, I" uniqKey="Vergote I">I Vergote</name></author><author><name sortKey="Pignata, S" uniqKey="Pignata S">S Pignata</name></author><author><name sortKey="Ferrero, A" uniqKey="Ferrero A">A Ferrero</name></author><author><name sortKey="Sehouli, J" uniqKey="Sehouli J">J Sehouli</name></author><author><name sortKey="Lortholary, A" uniqKey="Lortholary A">A Lortholary</name></author><author><name sortKey="Kristensen, G" uniqKey="Kristensen G">G Kristensen</name></author><author><name sortKey="Jackisch, C" uniqKey="Jackisch C">C Jackisch</name></author><author><name sortKey="Joly, F" uniqKey="Joly F">F Joly</name></author><author><name sortKey="Brown, C" uniqKey="Brown C">C Brown</name></author><author><name sortKey="Le Fur, N" uniqKey="Le Fur N">N Le Fur</name></author><author><name sortKey="Du Bois, A" uniqKey="Du Bois A">A du Bois</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rustin, Gj" uniqKey="Rustin G">GJ Rustin</name></author><author><name sortKey="Van Der Burg, Me" uniqKey="Van Der Burg M">ME van der Burg</name></author><author><name sortKey="Griffin, Cl" uniqKey="Griffin C">CL Griffin</name></author><author><name sortKey="Guthrie, D" uniqKey="Guthrie D">D Guthrie</name></author><author><name sortKey="Lamont, A" uniqKey="Lamont A">A Lamont</name></author><author><name sortKey="Jayson, Gc" uniqKey="Jayson G">GC Jayson</name></author><author><name sortKey="Kristensen, G" uniqKey="Kristensen G">G Kristensen</name></author><author><name sortKey="Mediola, C" uniqKey="Mediola C">C Mediola</name></author><author><name sortKey="Coens, C" uniqKey="Coens C">C Coens</name></author><author><name sortKey="Qian, W" uniqKey="Qian W">W Qian</name></author><author><name sortKey="Parmar, Mk" uniqKey="Parmar M">MK Parmar</name></author><author><name sortKey="Swart, Am" uniqKey="Swart A">AM Swart</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rustin, Gjs" uniqKey="Rustin G">GJS Rustin</name></author><author><name sortKey="Timmers, P" uniqKey="Timmers P">P Timmers</name></author><author><name sortKey="Nelstrop, A" uniqKey="Nelstrop A">A Nelstrop</name></author><author><name sortKey="Shreeves, G" uniqKey="Shreeves G">G Shreeves</name></author><author><name sortKey="Bentzen, Sm" uniqKey="Bentzen S">SM Bentzen</name></author><author><name sortKey="Baron, B" uniqKey="Baron B">B Baron</name></author><author><name sortKey="Piccart, Mj" uniqKey="Piccart M">MJ Piccart</name></author><author><name sortKey="Bertelsen, K" uniqKey="Bertelsen K">K Bertelsen</name></author><author><name sortKey="Stuart, G" uniqKey="Stuart G">G Stuart</name></author><author><name sortKey="Cassidy, J" uniqKey="Cassidy J">J Cassidy</name></author><author><name sortKey="Eisenhauer, E" uniqKey="Eisenhauer E">E Eisenhauer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sankaranarayanan, R" uniqKey="Sankaranarayanan R">R Sankaranarayanan</name></author><author><name sortKey="Ferlay, J" uniqKey="Ferlay J">J Ferlay</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Therasse, P" uniqKey="Therasse P">P Therasse</name></author><author><name sortKey="Arbuck, Sg" uniqKey="Arbuck S">SG Arbuck</name></author><author><name sortKey="Eisenhauer, Ea" uniqKey="Eisenhauer E">EA Eisenhauer</name></author><author><name sortKey="Wanders, J" uniqKey="Wanders J">J Wanders</name></author><author><name sortKey="Kaplan, Rs" uniqKey="Kaplan R">RS Kaplan</name></author><author><name sortKey="Rubinstein, L" uniqKey="Rubinstein L">L Rubinstein</name></author><author><name sortKey="Verweij, J" uniqKey="Verweij J">J Verweij</name></author><author><name sortKey="Van Glabbeke, M" uniqKey="Van Glabbeke M">M Van Glabbeke</name></author><author><name sortKey="Van Oosterom, At" uniqKey="Van Oosterom A">AT van Oosterom</name></author><author><name sortKey="Christian, Mc" uniqKey="Christian M">MC Christian</name></author><author><name sortKey="Gwyther, Sg" uniqKey="Gwyther S">SG Gwyther</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vergote, I" uniqKey="Vergote I">I Vergote</name></author><author><name sortKey="Rustin, Gj" uniqKey="Rustin G">GJ Rustin</name></author><author><name sortKey="Eisenhauer, Ea" uniqKey="Eisenhauer E">EA Eisenhauer</name></author><author><name sortKey="Kristensen, Gb" uniqKey="Kristensen G">GB Kristensen</name></author><author><name sortKey="Pujade Lauraine, E" uniqKey="Pujade Lauraine E">E Pujade-Lauraine</name></author><author><name sortKey="Parmar, Mk" uniqKey="Parmar M">MK Parmar</name></author><author><name sortKey="Friedlander, M" uniqKey="Friedlander M">M Friedlander</name></author><author><name sortKey="Jakobsen, A" uniqKey="Jakobsen A">A Jakobsen</name></author><author><name sortKey="Vermorken, Jb" uniqKey="Vermorken J">JB Vermorken</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22240800</article-id><article-id pub-id-type="pmc">3322951</article-id><article-id pub-id-type="pii">bjc2011593</article-id><article-id pub-id-type="doi">10.1038/bjc.2011.593</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Studies</subject></subj-group></article-categories><title-group><article-title>CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial</article-title><alt-title alt-title-type="running">CALYPSO experience with CA-125</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Alexandre</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Coeffic</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Raban</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Pfisterer</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Mäenpää</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Chalchal</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Fitzharris</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Volgger</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Vergote</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Pisano</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Ferrero</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Pujade-Lauraine</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label><institution>Département d'Oncologie Médicale, Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre</institution>, site Hôtel-Dieu, Paris,<country>France</country></aff><aff id="aff2"><label>2</label><institution>NHMRC Clinical Trials Centre</institution>, Sydney,<country>Australia</country></aff><aff id="aff3"><label>3</label><institution>Medical Oncology Department, Hôpital des Diaconesses</institution>, Paris,<country>France</country></aff><aff id="aff4"><label>4</label><institution>Department of Medical Oncology, University Hospital of Milétrie</institution>, Poitiers,<country>France</country></aff><aff id="aff5"><label>5</label><institution>Department of Gynecology, Staedtisches Klinikum Solingen</institution>, Solingen,<country>Germany</country></aff><aff id="aff6"><label>6</label><institution>Department of Obstetrics and Gynecology, University of Tampere and Tampere University Hospital</institution>, Tampere,<country>Finland</country></aff><aff id="aff7"><label>7</label><institution>Department of Medicine, University of Saskatchewan. Allan Blair Cancer Centre</institution>, Regina,<country>Saskatchewan</country></aff><aff id="aff8"><label>8</label><institution>Christchurch Hospital</institution>, Christchurch,<country>New Zealand</country></aff><aff id="aff9"><label>9</label><institution>Department of Obstetrics and Gynecology, University Hospital Innsbruck</institution>, Innsbruck,<country>Austria</country></aff><aff id="aff10"><label>10</label><institution>University Hospital Leuven, Leuven Cancer Institute and Department of Gynaecological Oncology</institution>, Leuven,<country>Belgium</country></aff><aff id="aff11"><label>11</label><institution>Division of Medical Oncology, Uro-Gynecological Department, National Cancer Institute</institution>, Naples,<country>Italy</country></aff><aff id="aff12"><label>12</label><institution>Academic Division of Gynecologic Oncology, Mauriziano Hospital</institution>, Torino,<country>Italy</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>jerome.alexandre@htd.aphp.fr</email></corresp></author-notes><pub-date pub-type="ppub"><day>14</day><month>02</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>12</day><month>01</month><year>2012</year></pub-date><volume>106</volume><issue>4</issue><fpage>633</fpage><lpage>637</lpage><history><date date-type="received"><day>05</day><month>09</month><year>2011</year></date><date date-type="rev-recd"><day>22</day><month>11</month><year>2011</year></date><date date-type="accepted"><day>16</day><month>12</month><year>2011</year></date></history><permissions><copyright-statement>Copyright © 2012 Cancer Research UK</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><sec><title>Background:</title><p>CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remains controversial. CALYPSO is a large randomised trial incorporating CA-125 (GCIG criteria) and symptomatic deterioration in addition to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (radiological) to determine progression.</p></sec><sec><title>Methods:</title><p>In all, 976 patients with platinum-sensitive ROC were randomised to carboplatin–paclitaxel (C-P) or carboplatin-pegylated liposomal doxorubicin (C-PLD). CT-scan and CA-125 were performed every 3 months until progression.</p></sec><sec><title>Results:</title><p>In all, 832 patients (85%) progressed, with 60% experiencing a first radiological progression, 10% symptomatic progression, and 28% CA-125 progression without evidence of radiological or symptomatic progression. The benefit of C-PLD <italic>vs</italic> C-P in progression-free survival was not influenced by type of first progression (hazard ratio 0.85 (95% confidence interval (CI): 0.66–1.10) and 0.84 (95% CI: 0.72–0.98) for CA-125 and RECIST, respectively). In patients with CA-125 first progression who subsequently progressed radiologically, a delay of 2.3 months was observed between the two progression types. After CA-125 first progression, median time to new treatment was 2.0 months. In all, 81%of the patients with CA-125 or radiological first progression and 60% with symptomatic first progression received subsequent treatment.</p></sec><sec><title>Conclusion:</title><p>CA-125 and radiological tests performed similarly in determining progression with C-PLD or C-P. Additional follow-up with CA-125 measurements was not associated with overtreatment.</p></sec></abstract><kwd-group><kwd>ovarian cancer</kwd><kwd>CA-125</kwd><kwd>pegylated liposomal doxorubicin</kwd><kwd>carboplatin</kwd><kwd>paclitaxel</kwd><kwd>radiological</kwd></kwd-group></article-meta></front><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>Cumulative incidence of type of progression.</p></caption><graphic xlink:href="bjc2011593f1"></graphic></fig><fig id="fig2"><label>Figure 2</label><caption><p>Differences between C-PLD and C-P arms according to type of first progression. <sup>*</sup>Indicates time to radiological progression post-CA-125 elevation including time to RECIST failure for those patients without prior CA-125 elevation. Abbreviations: C-P=carboplatin–paclitaxel; C-PLD=carboplatin-pegylated liposomal doxorubicin; RECIST=response evaluation criteria in solid tumours.</p></caption><graphic xlink:href="bjc2011593f2"></graphic></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Type of first progression</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="char" char="("></col><col align="char" char="("></col><col align="char" char="("></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="3" align="center" valign="top" char="(" charoff="50"><bold>Number of patients (%)</bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Type of first progression</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>Early progression (<italic>n</italic>=146)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>Other progressions (<italic>n</italic>=686)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>All progressions (<italic>n</italic>=832)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">RECIST<xref ref-type="fn" rid="t1-fn2">a</xref></td><td align="char" valign="top" char="(" charoff="50">88 (61)</td><td align="char" valign="top" char="(" charoff="50">414 (60)</td><td align="char" valign="top" char="(" charoff="50">502 (60)</td></tr><tr><td align="left" valign="top" charoff="50">Isolated CA-125 doubling (GCIG)</td><td align="char" valign="top" char="(" charoff="50">28 (19)</td><td align="char" valign="top" char="(" charoff="50">204 (30)</td><td align="char" valign="top" char="(" charoff="50">232 (28)</td></tr><tr><td align="left" valign="top" charoff="50">Symptomatic<xref ref-type="fn" rid="t1-fn3">b</xref></td><td align="char" valign="top" char="(" charoff="50">29 (19)</td><td align="char" valign="top" char="(" charoff="50">54 (8)</td><td align="char" valign="top" char="(" charoff="50">83 (10)</td></tr><tr><td align="left" valign="top" charoff="50">Unspecified/other<xref ref-type="fn" rid="t1-fn4">c</xref></td><td align="char" valign="top" char="(" charoff="50">1 (1)</td><td align="char" valign="top" char="(" charoff="50">14 (2)</td><td align="char" valign="top" char="(" charoff="50">15 (2)</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: GCIG=Gynaecologic Cancer Intergroup; RECIST=Response Evaluation Criteria in Solid Tumours.</p></fn><fn id="t1-fn2"><label>a</label><p>Including patients who experienced CA-125 or clinical progression within 7 days before or after RECIST progression.</p></fn><fn id="t1-fn3"><label>b</label><p>Including patients who experienced biological CA-125 within 3 days before or after clinical progression.</p></fn><fn id="t1-fn4"><label>c</label><p>Including tumour progression observed during surgical procedure.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Baseline parameters associated with RECIST, CA125, or symptomatic progression (PD)</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="char" char="."></col><col align="char" char="."></col><col align="char" char="."></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="3" align="center" valign="top" char="." charoff="50"><bold>Type of first PD</bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"> </th><th align="center" valign="top" char="." charoff="50"><bold>RECIST (%)</bold></th><th align="center" valign="top" char="." charoff="50"><bold>CA-125 (%)</bold></th><th align="center" valign="top" char="." charoff="50"><bold>Symptomatic (%)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Proportion of progressions<xref ref-type="fn" rid="t2-fn2">a</xref></td><td align="char" valign="top" char="." charoff="50">60</td><td align="char" valign="top" char="." charoff="50">28</td><td align="char" valign="top" char="." charoff="50">10</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Histological subtype</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Mucinous (<italic>n</italic>=14)</td><td align="char" valign="top" char="." charoff="50">50</td><td align="char" valign="top" char="." charoff="50">21</td><td align="char" valign="top" char="." charoff="50">14</td></tr><tr><td align="left" valign="top" charoff="50"> Other (<italic>n</italic>=818)</td><td align="char" valign="top" char="." charoff="50">61</td><td align="char" valign="top" char="." charoff="50">29</td><td align="char" valign="top" char="." charoff="50">12</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Measurable disease (TL)</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Yes (<italic>n</italic>=551)</td><td align="char" valign="top" char="." charoff="50">68</td><td align="char" valign="top" char="." charoff="50">22</td><td align="char" valign="top" char="." charoff="50">9</td></tr><tr><td align="left" valign="top" charoff="50"> No (<italic>n</italic>=281)</td><td align="char" valign="top" char="." charoff="50">46</td><td align="char" valign="top" char="." charoff="50">39</td><td align="char" valign="top" char="." charoff="50">12</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Assessable by CA-125</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Yes (<italic>n</italic>=587)</td><td align="char" valign="top" char="." charoff="50">58</td><td align="char" valign="top" char="." charoff="50">32</td><td align="char" valign="top" char="." charoff="50">13</td></tr><tr><td align="left" valign="top" charoff="50"> No (<italic>n</italic>=243)</td><td align="char" valign="top" char="." charoff="50">65</td><td align="char" valign="top" char="." charoff="50">18</td><td align="char" valign="top" char="." charoff="50">9</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td><td align="char" valign="top" char="." charoff="50"> </td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Treatment arm</italic></td></tr><tr><td align="left" valign="top" charoff="50"> C-P (<italic>n</italic>=443)</td><td align="char" valign="top" char="." charoff="50">58</td><td align="char" valign="top" char="." charoff="50">28</td><td align="char" valign="top" char="." charoff="50">10</td></tr><tr><td align="left" valign="top" charoff="50"> C-PLD (<italic>n</italic>=389)</td><td align="char" valign="top" char="." charoff="50">63</td><td align="char" valign="top" char="." charoff="50">27</td><td align="char" valign="top" char="." charoff="50">9</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Abbreviations: C-P=carboplatin–paclitaxel; C-PLD=carboplatin-pegylated liposomal doxorubicin; PD=progressive disease; RECIST=Response Evaluation Criteria in Solid Tumours.</p></fn><fn id="t2-fn2"><label>a</label><p>The totals of the values do not equal 100% because progression of unspecified type and other progressions (<italic>n</italic>=15) were not shown, patients not progressed excluded.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3"><label>Table 3</label><caption><title>Type of first progression and post-study therapy</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="char" char="."></col><col align="char" char="."></col><col align="char" char="."></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="3" align="center" valign="top" char="." charoff="50"><bold>Type of first progression</bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"> </th><th align="center" valign="top" char="." charoff="50"><bold>RECIST</bold></th><th align="center" valign="top" char="." charoff="50"><bold>CA-125</bold></th><th align="center" valign="top" char="." charoff="50"><bold>Symptomatic</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Total number of progressions</td><td align="char" valign="top" char="." charoff="50">502</td><td align="char" valign="top" char="." charoff="50">232</td><td align="char" valign="top" char="." charoff="50">83</td></tr><tr><td align="left" valign="top" charoff="50">Number of patients receiving new treatment after progression <italic>n</italic>, (%)</td><td align="char" valign="top" char="." charoff="50">406 (81)</td><td align="char" valign="top" char="." charoff="50">189 (81)</td><td align="char" valign="top" char="." charoff="50">50 (60)</td></tr><tr><td align="left" valign="top" charoff="50">Median time from first progression to new treatment (days)</td><td align="char" valign="top" char="." charoff="50">28</td><td align="char" valign="top" char="." charoff="50">60</td><td align="char" valign="top" char="." charoff="50">32</td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>Abbreviation: RECIST=Response Evaluation Criteria in Solid Tumours.</p></fn></table-wrap-foot></table-wrap></floats-group></pmc><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Autriche</li><li>Belgique</li><li>Finlande</li><li>France</li><li>Italie</li><li>Nouvelle-Zélande</li></country></list><tree><noCountry><name sortKey="Chalchal, H" sort="Chalchal, H" uniqKey="Chalchal H" first="H" last="Chalchal">H. Chalchal</name></noCountry><country name="France"><noRegion><name sortKey="Alexandre, J" sort="Alexandre, J" uniqKey="Alexandre J" first="J" last="Alexandre">J. Alexandre</name></noRegion><name sortKey="Coeffic, D" sort="Coeffic, D" uniqKey="Coeffic D" first="D" last="Coeffic">D. Coeffic</name><name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E" last="Pujade-Lauraine">E. Pujade-Lauraine</name><name sortKey="Raban, N" sort="Raban, N" uniqKey="Raban N" first="N" last="Raban">N. Raban</name></country><country name="Australie"><noRegion><name sortKey="Brown, C" sort="Brown, C" uniqKey="Brown C" first="C" last="Brown">C. Brown</name></noRegion></country><country name="Allemagne"><noRegion><name sortKey="Pfisterer, J" sort="Pfisterer, J" uniqKey="Pfisterer J" first="J" last="Pfisterer">J. Pfisterer</name></noRegion></country><country name="Finlande"><noRegion><name sortKey="M Enp, J" sort="M Enp, J" uniqKey="M Enp J" first="J" last="M Enp">J. M Enp</name></noRegion></country><country name="Nouvelle-Zélande"><noRegion><name sortKey="Fitzharris, B" sort="Fitzharris, B" uniqKey="Fitzharris B" first="B" last="Fitzharris">B. Fitzharris</name></noRegion></country><country name="Autriche"><noRegion><name sortKey="Volgger, B" sort="Volgger, B" uniqKey="Volgger B" first="B" last="Volgger">B. Volgger</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="Vergote, I" sort="Vergote, I" uniqKey="Vergote I" first="I" last="Vergote">I. Vergote</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Pisano, C" sort="Pisano, C" uniqKey="Pisano C" first="C" last="Pisano">C. Pisano</name></noRegion><name sortKey="Ferrero, A" sort="Ferrero, A" uniqKey="Ferrero A" first="A" last="Ferrero">A. Ferrero</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C77 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000C77 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= PMC:3322951
|texte= CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:22240800" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |